ArticleNature2025
Cancer-induced nerve injury promotes resistance to anti-PD-1 therapy.
Abstract read
In one paragraph
Article in Nature, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 69 papers.
0numbers the graph read from it
0cells of the map it votes in
69citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
69 citing papers in PubMed.
- Durvalumab and cediranib with and without olaparib in recurrent ovarian cancer: a phase II proof-of-concept study.Nature communications · 2026Trial
- Neuro-immune interactions in tumors, immune-related disorders, and infections.Signal transduction and targeted therapy · 2026Review
- Review
- Neural-tumor interactions: bidirectional regulatory mechanisms and nervous system-targeted tumor therapeutic strategies.Biomarker research · 2026Review
- Review
- Decoding neuro-tumor interactions in pancreatic cancer: mechanisms, immunosuppressive networks and therapeutic opportunities.Molecular biomedicine · 2026Review
- Central nervous system and cancer: mechanistic insights and therapeutic opportunities CNS and cancer: a review.Medical oncology (Northwood, London, England) · 2026Review
- Defect-Engineered BiOAdvanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Neuro-immune crosstalk in lung cancer brain metastasis: mechanisms, therapeutic targets, and translational opportunities.Medical oncology (Northwood, London, England) · 2026Review
- Epithelial-mesenchymal transition in carcinoma: navigating phenotypic states to target resistance and metastasis.Cancer metastasis reviews · 2026Review
- A cuproptosis-inducing covalent organic framework synergizes with oncolytic virus for tumor radiotherapy.Nature communications · 2026Article
- Decoding osteosarcoma mechanobiology: PIEZO channels in tumor progression, immune remodeling, and pain.Cancer metastasis reviews · 2026Review
- Neural regulation of tumor immunity: emerging opportunities to enhance cancer immunotherapy.Experimental & molecular medicine · 2026Review
- Sciatic nerve atrophy as a predictor of impaired wound healing in patients with chronic limb-threatening ischemia following endovascular therapy: A prospective pilot study.Vascular medicine (London, England) · 2026Article
- Baseline IL-6, IL-8, IFN-ω, and perforin as prognostic biomarkers in immune checkpoint inhibitor-treated metastatic non-small cell lung cancer.Translational lung cancer research · 2026Article
- Photothermal-Chemotherapeutic Microneedle Patch Coloaded with HMnOACS applied materials & interfaces · 2026Article
- Perineural Invasion, Pain and Immunosuppression Across Solid Tumours.Current oncology (Toronto, Ont.) · 2026Review
- Article
- Neural regulation of cancer: from synaptic integration to neuro-immune regulation.Cellular oncology (Dordrecht, Netherlands) · 2026Review
- TLR7 signature of tumour innervation reveals two distinct pathways of triple-negative breast cancer progression.British journal of cancer · 2026Article
9 more citing papers are in PubMed but not listed here.
Corrections and comments
- Update of
Authors and funding
61 authors.
Erez N Baruch *Division of Cancer Medicine, Hematology and Oncology Fellowship program, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0001-6001-6598
Frederico O Gleber-Netto *Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0001-7847-9902
Priyadharsini Nagarajan *Department of Anatomical Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0002-5346-2669
Xiayu Rao *Department of Bioinformatics and Computational Biology, Division of Discovery Sciences, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Shamima Akhter *Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Tuany Eichwald *Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden.
Tongxin XieDepartment of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Mohammad BaloodDepartment of Biomedical and Molecular Sciences, Queen's University, Kingston, Ontario, Canada.
Adebayo AdewaleDepartment of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Shorook NaaraDepartment of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Hinduja N SathishkumarDepartment of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Shajedul IslamDepartment of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
William McCarthyDepartment of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Brandi J MattsonThe Neurodegeneration Consortium, Therapeutics Discovery Division, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Renata FerrarottoDepartment of Head and Neck Thoracic Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Michael K WongDepartment of Melanoma Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Michael A DaviesDepartment of Melanoma Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0002-0977-0912
Sonali JindalJames P. Allison Institute, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0002-3911-6815
Sreyashi BasuJames P. Allison Institute, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0002-5028-3833
Karine RoversiDepartment of Biomedical and Molecular Sciences, Queen's University, Kingston, Ontario, Canada.
Amin Reza NikpoorDepartment of Biomedical and Molecular Sciences, Queen's University, Kingston, Ontario, Canada.
Maryam AhmadiDepartment of Biomedical and Molecular Sciences, Queen's University, Kingston, Ontario, Canada.
Ali AhmadiDepartment of Biomedical and Molecular Sciences, Queen's University, Kingston, Ontario, Canada.ORCID 0000-0001-9926-8434
Catherine HarwoodDepartment of Dermatology, Royal London Hospital, Barts Health NHS Trust, London, UK.
Irene LeighDepartment of Dermatology, Royal London Hospital, Barts Health NHS Trust, London, UK.
Dennis GongCenter for Systems Biology, Krantz Family Center for Cancer Research, Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Paulino Tallón de LaraDivision of Cancer Medicine, Hematology and Oncology Fellowship program, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0001-7368-4798
Derrick L TaoDivision of Cancer Medicine, Hematology and Oncology Fellowship program, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0001-5306-0259
Tara M DavidsonDivision of Cancer Medicine, Hematology and Oncology Fellowship program, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Nadim J AjamiPlatform for Innovative Microbiome and Translational Research, Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0002-3808-8576
Andrew FutrealDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0001-8663-2671
Kunal RaiDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0003-2321-6894
Veena KochatDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Micah CastilloDepartment of Biology and Biochemistry, University of Houston Sequencing and Gene Editing Core, University of Houston, Houston, TX, USA.
Preethi GunaratneDepartment of Biology and Biochemistry, University of Houston Sequencing and Gene Editing Core, University of Houston, Houston, TX, USA.
Ryan P GoepfertPlatform for Innovative Microbiome and Translational Research, Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Sharia D HernandezDepartment of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0002-7746-0860
Nikhil I KhushalaniDepartment of Cutaneous Oncology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, USA.
Jing WangDepartment of Bioinformatics and Computational Biology, Division of Discovery Sciences, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. jingwang@mdanderson.org.ORCID 0000-0002-5398-0802
Stephanie S WatowichDepartment of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0003-1969-659X
George A CalinDepartment of Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0002-7427-0578
Michael R MigdenDepartment of Dermatology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Mona YuanTranslational Research Center, New York University College of Dentistry, New York, NY, USA.ORCID 0009-0008-5647-2572
Naijiang LiuTranslational Research Center, New York University College of Dentistry, New York, NY, USA.ORCID 0009-0005-2477-7636
Yi YeTranslational Research Center, New York University College of Dentistry, New York, NY, USA.
William L HwangCenter for Systems Biology, Krantz Family Center for Cancer Research, Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.ORCID 0000-0003-4514-8837
Paola D VermeerCancer Biology and Immunotherapies Group, Sanford Research, Sioux Falls, SD, USA.ORCID 0000-0003-2370-8223
Nisha J D'SilvaDepartment of Periodontics and Oral Medicine, The University of Michigan, Ann Arbor, MI, USA.ORCID 0000-0001-7030-3187
Yuri L BunimovichDepartment of Dermatology, University of Pittsburgh, Pittsburgh, PA, USA.ORCID 0000-0002-7920-8781
Dan YanivDepartment of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Jared K BurksDepartment of Hematopoietic Biology & Malignancies, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0002-6173-9074
Javier GomezDepartment of Hematopoietic Biology & Malignancies, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0002-6579-744X
Patrick M DoughertyDepartment of Pain Medicine, Division of Anesthesiology, Critical Care, and Pain Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0002-2177-2734
Kenneth Y TsaiDepartment of Pathology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, USA. Kenneth.Tsai@moffitt.org.ORCID 0000-0001-5325-212X
James P AllisonJames P. Allison Institute, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Padmanee SharmaJames P. Allison Institute, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0003-4658-055X
Jennifer A WargoPlatform for Innovative Microbiome and Translational Research, Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0003-3438-7576
Jeffrey N MyersDepartment of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0003-4767-3408
Sebastien TalbotDepartment of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden. sebas.talbot@gmail.com.ORCID 0000-0001-9932-7174
Neil D GrossDepartment of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. Ndgross@mdanderson.org.ORCID 0000-0002-9427-0743
Moran AmitDepartment of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. Moranamit@gmail.com.ORCID 0000-0002-9720-7766
Funding
Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI DIANE BODURKA · 1985 to 2026
$290.8MTRANSLATIONAL RESEARCHP30CA076292 · NCI · UNIVERSITY OF SOUTH FLORIDA · PI John L. Cleveland · 1998 to 2026
$93.5MTropism Enhanced Oncolytic Adenovirus for the Treatment of Brain TumorsP50CA127001 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Juan Fueyo, FREDERICK F LANG · 2008 to 2026
$41.2MUPR/MDACC Partnership for Excellence in Cancer Research(Parent Grant U54 CA096297)U54CA096297 · NCI · UNIVERSITY OF PUERTO RICO MED SCIENCES · PI KAREN J ORTIZ · 2002 to 2026
$36.9MUPR/MDACC Partnership for Excellence in Cancer Research (Luis Segarra supplement)U54CA096300 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI SHARON Hermes GIORDANO, Paul A Scheet · 2002 to 2026
$23.8MThe University of Texas MD Anderson Cancer Center SPORE in MelanomaP50CA221703 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI WARGO, JENNIFER A. · 2019 to 2023
$10.3MImproving Survival in Oral Cancer by Disruption of Tumor ProgressionR35DE027551 · NIDCR · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI D'SILVA, NISHA J · 2017 to 2024
$8.1MEndosomal mechanisms signaling oral cancer painRM1DE033491 · NIDCR · NEW YORK UNIVERSITY · PI NIGEL W BUNNETT, Rajesh Khanna · 2023 to 2026
$6.4MTargeting HB-EGF and trigeminal EGFR for oral cancer pain and opioid toleranceR01DE032501 · NIDCR · NEW YORK UNIVERSITY · PI YE, YI · 2022 to 2025
$4.0MHarnessing the nervous system to overcome resistance to immunotherapy in oral cancerR01DE032018 · NIDCR · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Moran Amit, George A. Calin · 2022 to 2026
$3.5MDefining the Role of Tumor-Neutral Crosstalk in head and Neck Cancer Progression and Treatment ResistanceR37CA242006 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI AMIT, MORAN · 2020 to 2025
$3.4MNovel extra cellular RNA-based combinatorial RNA inhibition therapyUH3TR000943 · NCATS · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI CALIN, GEORGE A., LOPEZ-BERESTEIN, GABRIEL · 2015 to 2017
$3.2MNCATS NIH HHS UH3 TR000943NCI NIH HHS K08 CA270417NCI NIH HHS P30 CA016672NCI NIH HHS P30 CA076292NCI NIH HHS P50 CA127001NCI NIH HHS P50 CA221703NCI NIH HHS R01 CA182905NCI NIH HHS R01 CA200263NCI NIH HHS R01 CA222007NCI NIH HHS R01 CA250214NCI NIH HHS R01 CA266529NCI NIH HHS R01 CA272946NCI NIH HHS R37 CA242006NCI NIH HHS R50 CA243707NCI NIH HHS U54 CA096297NCI NIH HHS U54 CA096300NIAID NIH HHS R01 AI133822NIDCR NIH HHS R01 DE029493NIDCR NIH HHS R01 DE032018NIDCR NIH HHS R01 DE032501NIDCR NIH HHS R01 DE032712NIDCR NIH HHS R01 DE033674NIDCR NIH HHS R35 DE027551NIDCR NIH HHS RM1 DE033491NIGMS NIH HHS R01 GM122775
Abstract
Perineural invasion (PNI) is a well-established factor of poor prognosis in multiple cancer types
Indexed as
Drug Resistance, NeoplasmImmune Checkpoint InhibitorsNeoplasmsPeripheral Nerve InjuriesProgrammed Cell Death 1 ReceptorAnimalsCarcinoma, Squamous CellFemaleHumansInflammationInterferon Type IInterleukin-6MaleMelanomaMiceNeoplasm InvasivenessIfnar1 protein, mouseImmune Checkpoint InhibitorsInterferon Type IInterleukin-6PDCD1 protein, humanProgrammed Cell Death 1 ReceptorReceptor, Interferon alpha-beta
Identifiers
What Socratic holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.